Natural Capsules Clarifies Objects of Preferential Issue for Fund Utilization
Natural Capsules Ltd · Others (Uncategorized) · 04 Nov 2026, 6:07 pm
Natural Capsules Clarifies Objects of Preferential Issue for Fund Utilization Natural Capsules Limited issued clarifications on 4th Nov'26 regarding the utilization of proceeds from its preferential issue of equity shares and convertible warrants. The company intends to allocate proceeds of ₹2.00 cr (Item 1) and ₹8.01 cr (Item 2) toward working capital requirements and capital expansion. Working capital allocations will cover raw material procurement, operational costs, employee expenses, and statutory obligations. Capital expansion proceeds will fund plant modernization, manufacturing capacity additions, process automation, and potential acquisition or establishment of an additional unit.
Original exchange filing (PDF)
More announcements from Natural Capsules Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sunil Laxminarayana Mundra · 16 Nov 2026
- Please find enclosed herewith copy of Investor Presentation in connection with Q2 Financial Results. · 16 Nov 2026
- Please find enclosed herewith Press Release made to Investors and Analysts in connection with Q2 Financials. · 16 Nov 2026
- Pursuant to Regulation 30 and Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company will hold .... · 19 Nov 2026
- We wish to inform you that due to an inadvertent typographical error in the decimal placement in the Consolidated Segment- Wise Revenue, Results & Capital Employed statement we are submitting .... · 15 Nov 2026
- Approve the Allotment of Securities on Preferential Basis. · 14 Nov 2026
- In order to close the matter and maintain compliance harmony, the company has deposited the requisite fine amount as demanded by the Stock Exchanges. · 14 Nov 2026
- 1. Approved the Unaudited Consolidated & Standalone Financial Results of the Company for the Quarter and Half Yearly ended September, 2026. 2. Approved the Allotment of Securities on .... · 14 Nov 2026
